Because detection of Rep was significantly associated with a M2-like polarization of MPs (CD68+CD163+) over all distances tested, this widespread tumor-promoting immune landscape might represent a very broad—not locally limited—risk signature and biomarker for CRC, which is available for testing throughout the entire mucosa. This evidence concerns the gene CD163 and colorectal carcinoma.